Skip to main content
. 2022 Mar 8;17(2):112–121. doi: 10.30699/IJP.2022.538690.2721

Table 3.

Prescribed antifungals in cases of cerebral mucormycosis plus the results of the multivariable logistic regression in cases who survived or died following cerebral mucormycosis

P-value OR (95% Cl) Dead
n (%)
N=136
Survived
n (%)
N=209
Total
n (%)
N=345
Antifungals
0. 758 0.7 (0.1-4.2) 2 (1.4) 4 (1.9) 6 (1.7) Voriconazole
0.554 1.4 (0.7-1.7) 76 (55.9) 110 (52.6) 186 (53.9) Amphotericin B-Deoxycholate
0. 900 1.6 (1.5-1.8) - 1 (0.4) 1 (0.3) Anidulafungin
0. 005 2.5 (2.2-2.9) 5 (3.6) - 5 (1.4) Caspofungin
0. 553 0.6 (0.1-3.1) 2 (1.4) 5 (2.3) 7 (2) Fluconazole
0.942 1.0 (0.3-2.9) 5(3.7%) 8(3.8%) 13 (3.8) Flucytosine
0.900 1.5 (2.1-11.9) 2 (1.4) 2 (0.9) 4 (1.2) Isavuconazole
0. 037 2.4 (1.2-5) 6 (4.4) 2 (0.9) 8 (2.3) Itraconazole
0.900 1.5 (0.2-11.09) 2 (1.4) 2 (0.9) 4 (1.3) Ketoconazole
0. 003 2.09 (1.2-3.4) 46 (33.8) 41(19.6) 87 (25.2) Liposomal Amphotericin B
0.758 0.7 (0.1-4.2) 2 (1.4) 4 (1.9) 6 (1.7) Micafungin
0. 9 1.6 (1.5-1.8) - 1 (0.4) 1 (0.3) Nystatin
0. 008 2.49 (1.2-5.00) 22 (16.1) 15 (7.1) 37 (10.7) Posaconazole